BLASUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROLVEDON (eflapegrastim-xnst) is a long-acting granulocyte colony-stimulating factor (G-CSF) biologic approved by FDA in September 2022. It is a leukocyte growth factor indicated for reducing the duration of severe neutropenia in patients receiving myelosuppressive chemotherapy. The drug works by stimulating the production and release of neutrophils to support immune function during cancer treatment.
$0.662MPart D
PeakEarly-peak commercial trajectory with modest Part D penetration suggests growing adoption phase; team size likely expanding as market awareness increases.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ROLVEDON is a peak-stage biologic in supportive oncology with modest commercial scale and no active clinical pipeline, creating focused career opportunities in brand stewardship, field execution, and health economics rather than development roles. Professionals joining the team should expect stable, mature product management with emphasis on formulary penetration and payer reimbursement optimization.
Brand Manager
Worked on ROLVEDON at Spectrum Dynamics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.